The risk environment does not stand still. With ever-changing exposures transcending climate, geo-political, regulatory and legal it is as important as ever to partner with specialists who both understand the changing landscape and can provide long term tailored solutions.
MCI meet this challenge through a team of underwriters experienced in underwriting niche areas of property and casualty on an international basis.
Our aim is clear: to provide the highest calibre of insurance products to those industries and risks where in-depth expertise is key to adding value.
MCI Group includes our holding company and regulated trading entities, and predominantly trades via its own Syndicate 1902.
Lloyd’s Syndicate 1902 underwrites our existing core MCI classes as well as launching several new and innovative products which have scientific and research-driven underwriting characteristics.
Syndicate 1902’s vision is to create a global leader in science and research-led risk transfer with superior returns in evolving risk classes.
Despite recent economic pressures, the global pharmaceutical industry is forecast to grow significantly over the next 5-10 years.
The term ‘medical device’ covers a vast range of equipment, from simple tongue depressors to the most sophisticated life-support products.
Within the life science industry successful product research is the key to sustaining a meaningful product pipeline.
New procedures are practiced and trialled every week with standards and expectations higher than ever.
Whilst the language used in liability risk management has evolved since Dr. Johnson’s era, the dilemma has not.
Typically, we fight off minor infections with no long-term consequences, but these pathogens also have the power to cause potentially devastating outbreaks.
Investing in the research of drug molecules has and continues to be one which has a high degree of risk.